Cantor Fitzgerald Has Weak Outlook for CRSP FY2025 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, February 19th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings of ($6.91) per share for the year, down from their prior estimate of ($5.08). Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.03) per share.

CRSP has been the subject of a number of other research reports. Citigroup cut their price objective on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research report on Tuesday. Barclays upped their target price on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Bank of America dropped their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, Chardan Capital dropped their target price on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $74.40.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $50.46 on Friday. CRISPR Therapeutics has a 1 year low of $36.52 and a 1 year high of $91.10. The firm has a fifty day moving average price of $42.16 and a 200-day moving average price of $46.07.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors have recently modified their holdings of CRSP. Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $39,000. Western Pacific Wealth Management LP increased its position in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after acquiring an additional 500 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics during the third quarter worth approximately $40,000. Darwin Wealth Management LLC purchased a new position in shares of CRISPR Therapeutics during the third quarter worth approximately $43,000. Finally, Eastern Bank purchased a new position in shares of CRISPR Therapeutics during the third quarter worth approximately $70,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.